Judge Rules TKT Infringes Amgen Erythropoietin Patents

Law360, New York (October 16, 2004, 12:00 AM EDT) -- A federal judge has ruled in biotech company Amgen Inc.’s favor in its seven-year legal battle against Transkaryotic Therapies Inc. (TKT) and Aventis Pharmaceuticals Inc. over patents for an anemia treatment.

In a 290-page ruling, Judge William G. Young of U.S. District Court for the District of Massachusetts upheld four of Amgen's patent claims and said two of them had been infringed by TKT.

The patents cover the production of erythropoietin, a natural hormone produced by the kidneys that stimulates the production of red blood cells....
To view the full article, register now.